BRPI0518489A2 - modificaÇÕes cristalinas estÁveis de cloreto de dotap - Google Patents

modificaÇÕes cristalinas estÁveis de cloreto de dotap

Info

Publication number
BRPI0518489A2
BRPI0518489A2 BRPI0518489-4A BRPI0518489A BRPI0518489A2 BR PI0518489 A2 BRPI0518489 A2 BR PI0518489A2 BR PI0518489 A BRPI0518489 A BR PI0518489A BR PI0518489 A2 BRPI0518489 A2 BR PI0518489A2
Authority
BR
Brazil
Prior art keywords
stable crystalline
dotap chloride
crystalline modifications
modifications
chloride
Prior art date
Application number
BRPI0518489-4A
Other languages
English (en)
Inventor
Michael Platscher
Alfred Hedinger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to BR122019018186A priority Critical patent/BR122019018186B8/pt
Publication of BRPI0518489A2 publication Critical patent/BRPI0518489A2/pt
Publication of BRPI0518489B1 publication Critical patent/BRPI0518489B1/pt
Publication of BRPI0518489B8 publication Critical patent/BRPI0518489B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MODIFICAÇÕES CRISTALINAS ESTÁVEIS DE CLORETO DE DOTAP. A presente invenção refere-se a cloreto de DOTAP puro em termos enantioméricos e modificações cristalinas estáveis de cloreto de (2R,S)-, (2S)- e (2R)-DOTAP, um processo para a preparação destas modificações, e o uso deles como um constituinte para a preparação de medicamentos.
BRPI0518489A 2004-11-26 2005-11-07 cloreto de (2r)-dotap enantiomericamente puro, seu uso, e composição farmacêutica BRPI0518489B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019018186A BR122019018186B8 (pt) 2004-11-26 2005-11-07 cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004057303.4 2004-11-26
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid
PCT/EP2005/011874 WO2006056312A1 (de) 2004-11-26 2005-11-07 Stabile kristallmodifikationen von dotap chlorid

Publications (3)

Publication Number Publication Date
BRPI0518489A2 true BRPI0518489A2 (pt) 2008-11-25
BRPI0518489B1 BRPI0518489B1 (pt) 2020-03-31
BRPI0518489B8 BRPI0518489B8 (pt) 2021-05-25

Family

ID=35789283

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019018186A BR122019018186B8 (pt) 2004-11-26 2005-11-07 cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica
BRPI0518489A BRPI0518489B8 (pt) 2004-11-26 2005-11-07 cloreto de (2r)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019018186A BR122019018186B8 (pt) 2004-11-26 2005-11-07 cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Country Status (20)

Country Link
US (2) US8853283B2 (pt)
EP (1) EP1814843B1 (pt)
JP (1) JP4880612B2 (pt)
KR (1) KR101249370B1 (pt)
CN (2) CN101065350A (pt)
AU (1) AU2005309107B2 (pt)
BR (2) BR122019018186B8 (pt)
CA (1) CA2589218C (pt)
DE (1) DE102004057303A1 (pt)
ES (1) ES2545906T3 (pt)
HU (1) HUE027554T2 (pt)
IL (1) IL183324A (pt)
MX (1) MX2007006128A (pt)
NO (1) NO338885B1 (pt)
NZ (2) NZ582382A (pt)
PL (1) PL1814843T3 (pt)
PT (1) PT1814843E (pt)
RU (1) RU2463291C2 (pt)
WO (1) WO2006056312A1 (pt)
ZA (1) ZA200705169B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2276495B1 (en) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
KR101974231B1 (ko) * 2011-05-20 2019-04-30 메르크 파텐트 게엠베하 Ｄｏｔａｐ 클로라이드의 안정한 결정 개질
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2013039989A1 (en) * 2011-09-12 2013-03-21 Pds Biotechnology Corporation Particluate vaccine formulations
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CA3058782A1 (en) * 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
CZ299809B6 (cs) * 1996-05-08 2008-12-03 Nika Health Products Limited Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy
CN1138533C (zh) * 1996-09-13 2004-02-18 利普森有限公司 脂质体
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
CA2589218A1 (en) 2006-06-01
KR101249370B1 (ko) 2013-04-01
IL183324A0 (en) 2007-09-20
JP4880612B2 (ja) 2012-02-22
US20080014254A1 (en) 2008-01-17
BR122019018186B8 (pt) 2021-07-27
US20140370081A1 (en) 2014-12-18
EP1814843A1 (de) 2007-08-08
HK1178143A1 (zh) 2013-09-06
ES2545906T3 (es) 2015-09-16
US9457087B2 (en) 2016-10-04
CN102796016A (zh) 2012-11-28
AU2005309107B2 (en) 2011-07-21
CN101065350A (zh) 2007-10-31
NO20073286L (no) 2007-06-25
EP1814843B1 (de) 2015-06-24
RU2007123673A (ru) 2009-01-10
IL183324A (en) 2013-10-31
CN102796016B (zh) 2015-09-02
ZA200705169B (en) 2008-08-27
KR20070084501A (ko) 2007-08-24
NZ582382A (en) 2010-08-27
BR122019018186B1 (pt) 2021-03-09
PL1814843T3 (pl) 2015-11-30
MX2007006128A (es) 2007-07-13
WO2006056312A1 (de) 2006-06-01
BRPI0518489B8 (pt) 2021-05-25
JP2008521757A (ja) 2008-06-26
CA2589218C (en) 2013-12-17
DE102004057303A1 (de) 2006-06-01
PT1814843E (pt) 2015-10-13
NZ556060A (en) 2010-03-26
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
US8853283B2 (en) 2014-10-07
HUE027554T2 (en) 2016-10-28
AU2005309107A1 (en) 2006-06-01
BRPI0518489B1 (pt) 2020-03-31

Similar Documents

Publication Publication Date Title
BRPI0518489A2 (pt) modificaÇÕes cristalinas estÁveis de cloreto de dotap
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
CR8428A (es) Agente endoparasiticidas para la administracion topica
NO20082793L (no) Nye tiofenderivater
HUE059635T2 (hu) Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
BRPI0519474A2 (pt) derivados de quinazolina para inibir o crescimento de cÉlulas cancerosas e mÉtodo para a preparaÇço destes
CL2007003326A1 (es) Compuestos derivados de pirrol[2,3-b]piridina, moduladores de la actividad del c-fms y/o el c-kit; composicion farmaceutica; y uso para el tratamiento de tumores de celulas mamarias, asma, artritis reumatoide, enfermedad de parkinson, entre otras.
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MX2010004576A (es) Derivados de pirimidina novedosos.
EA201170703A1 (ru) Производные адамантилбензамида
PL2626420T3 (pl) Polinukleotydy kodujące epitopy hTERT ograniczone do MHC klasy I HLA-B7, ich analogi lub poliepitopy
UY30448A1 (es) Derivados de ureas de piperidina o pirrolidina, su preparacion y su aplicacion en terapéutica
BRPI0509184A (pt) composições farmacêuticas
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
GT200800173A (es) Medicamentos que contienen fluoroquinolonas
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
MY160372A (en) Composition for improving brain function and method for improving brain function
BRPI0620229A8 (pt) formulação
BRPI0517390A (pt) processo para a preparação de derivados de [1,4,5]-oxadiazepina
WO2009017719A3 (en) Modulators of ccr9 receptor and methods of use thereof
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
AU2009235634A8 (en) Substituted sulfonamide derivatives
DK1729732T3 (da) Anioniske hydrogelmatricer med pH-afhængig frigivelse som lægemiddelbærere

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF